Alveus Therapeutics, Inc. clinical trial pipeline

2 trials changed in the last 30 days: 0 stopped, 0 with notable changes, 2 with minor changes only.

1. Minor

   ALV-100 to Assess Safety, Tolerability, and PK/PD in…ALV-100 to Assess Safety, Tolerability, and PK/PD in Overweight/Obese · or Without T2D

   Enrollment closed, study ongoing

   Also in this update: Primary completion pushed from Apr 2027 to Oct 2027

   Alveus Therapeutics, Inc.·Phase 1· NCT07399678· Registry history of NCT07399678 on ClinicalTrials.gov (opens the registry)

   Oct 16, 2026

2. Minor

   PRESERVE · Effect and Safety of ALV-100 on Maintenance of…PRESERVE · Effect and Safety of ALV-100 on Maintenance of Weight Loss

   Trial sites expanded: 12 → 20 locations

   Alveus Therapeutics, Inc.·Phase 2· NCT07837973· Registry history of NCT07837973 on ClinicalTrials.gov (opens the registry)

   Oct 15, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.